09.06.2022 11:00:57
|
Takeda: TAK-003 Shows 84.1% Vaccine Efficacy Against Hospitalized Dengue In Long-term TIDES Trial
(RTTNews) - Takeda (TAK) said its dengue vaccine candidate, TAK-003, prevented 84% of hospitalized dengue cases and 61% of symptomatic dengue cases, with no important safety risks identified, in the overall population including both seropositive and seronegative individuals through four and a half years after vaccination in the phase 3 Tetravalent Immunization against Dengue Efficacy Study trial. The company said these long-term results supplement previously published TIDES data that showed the candidate vaccine met its primary endpoint of overall vaccine efficacy against virologically-confirmed dengue.
The company noted that, while the long-term follow-up for the primary two-dose series has been completed, the TIDES trial remains ongoing to evaluate the safety and efficacy of a booster dose.
TAK-003 is undergoing regulatory review for the prevention of dengue disease in children and adults in the European Union and select dengue-endemic countries.
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Takeda Pharmaceutical Co Ltd. (spons. ADRs)mehr Nachrichten
30.10.24 |
Ausblick: Takeda Pharmaceutical präsentiert Quartalsergebnisse (finanzen.net) | |
16.10.24 |
Erste Schätzungen: Takeda Pharmaceutical mit Zahlen zum abgelaufenen Quartal (finanzen.net) | |
30.07.24 |
Ausblick: Takeda Pharmaceutical stellt das Zahlenwerk zum vergangenen Quartal vor (finanzen.net) | |
16.07.24 |
Erste Schätzungen: Takeda Pharmaceutical präsentiert Quartalsergebnisse (finanzen.net) |